It’s also why any dialogue about BPC-157 has to be grounded in humility. We've promising details, but we do not have many of the responses. Acknowledging this uncertainty is a trademark of responsible science.Beyond the dopamine issue, BPC-157 sits within a bigger discussion about peptide therapies